Funding for this research was provided by:
Received: 6 October 2021
Accepted: 11 March 2023
First Online: 25 March 2023
: Participants were recruited through an advocacy group with study materials approved by a centralized IRB, Schulman IRB.
: Not applicable.
: ALS, FT, REL, BP, and KS are employees of Adelphi Values, which conducted research on behalf of Blueprint Medicines. TG, ALB, and BM are employees of Blueprint Medicines and own stock in the company. CA received research funding and consultancy fees from Blueprint Medicines. FS is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Blueprint, Celldex, Genentech, Moxie, Novartis, and Uriach.